Bammer T, Hinder RA, Klaus A, Klingler PJ Five- to eight-year outcome of the first laparoscopic Nissen fundoplications. J Gastrointest Surg. 2001 Jan-Feb;5(1):42-8.
Corley DA, Kubo A Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis. Am J Gastroenterol. 2006 Nov;101(11):2619-28. Epub 2006 Sep 4. Review.
Donnelly PE, Salgado JJ, Gagne DD, et al Efficacy of laparoscopic Roux-en-Y gastric bypass (LRYGB) in obese patients with a previous fundoplication. Surg Obes Relat Dis 2007;3: 299-344.
Fass R The pathophysiological mechanisms of GERD in the obese patient. Dig Dis Sci. 2008 Sep;53(9):2300-6. doi: 10.1007/s10620-008-0411-y. Epub 2008 Jul 29.
Flum DR, Khan TV, Dellinger EP Toward the rational and equitable use of bariatric surgery. JAMA. 2007 Sep 26;298(12):1442-4.
Hampel H, Abraham NS, El-Serag HB Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005 Aug 2;143(3):199-211.
Higa KD, Boone KB, Ho T, Davies OG Laparoscopic Roux-en-Y gastric bypass for morbid obesity: technique and preliminary results of our first 400 patients. Arch Surg. 2000 Sep;135(9):1029-33; discussion 1033-4.
Houghton SG, Romero Y, Sarr MG Effect of Roux-en-Y gastric bypass in obese patients with Barrett's esophagus: attempts to eliminate duodenogastric reflux. Surg Obes Relat Dis. 2008 Jan-Feb;4(1):1-4; discussion 4-5. Epub 2007 Dec 19.
Ikramuddin S Surgical management of gastroesophageal reflux disease in obesity. Dig Dis Sci. 2008 Sep;53(9):2318-29. doi: 10.1007/s10620-008-0415-7. Epub 2008 Jul 29.
Jacobson BC Body mass index and the efficacy of acid-mediating agents for GERD. Dig Dis Sci. 2008 Sep;53(9):2313-7. doi: 10.1007/s10620-008-0414-8. Epub 2008 Jul 16. Review.
Kellogg TA, Andrade R, Maddaus M, Slusarek B, Buchwald H, Ikramuddin S Anatomic findings and outcomes after antireflux procedures in morbidly obese patients undergoing laparoscopic conversion to Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2007 Jan-Feb;3(1):52-7; discussion 58-9. Epub 2006 Nov 20.
Kubo A, Corley DA Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):872-8. Review.
Meguid MM, Glade MJ, Middleton FA Weight regain after Roux-en-Y: a significant 20% complication related to PYY. Nutrition. 2008 Sep;24(9):832-42. doi: 10.1016/j.nut.2008.06.027. Review.
Morgenthal CB, Lin E, Shane MD, Hunter JG, Smith CD Who will fail laparoscopic Nissen fundoplication? Preoperative prediction of long-term outcomes. Surg Endosc. 2007 Nov;21(11):1978-84. Epub 2007 Jul 11.
Patterson EJ, Davis DG, Khajanchee Y, Swanström LL Comparison of objective outcomes following laparoscopic Nissen fundoplication versus laparoscopic gastric bypass in the morbidly obese with heartburn. Surg Endosc. 2003 Oct;17(10):1561-5. Epub 2003 Jul 21.
Perez AR, Moncure AC, Rattner DW Obesity adversely affects the outcome of antireflux operations. Surg Endosc. 2001 Sep;15(9):986-9. Epub 2001 Jun 12.
Power C, Maguire D, McAnena O Factors contributing to failure of laparoscopic Nissen fundoplication and the predictive value of preoperative assessment. Am J Surg. 2004 Apr;187(4):457-63.
Raftopoulos I, Awais O, Courcoulas AP, Luketich JD Laparoscopic gastric bypass after antireflux surgery for the treatment of gastroesophageal reflux in morbidly obese patients: initial experience. Obes Surg. 2004 Nov-Dec;14(10):1373-80.
Smith SC, Edwards CB, Goodman GN Symptomatic and clinical improvement in morbidly obese patients with gastroesophageal reflux disease following Roux-en-Y gastric bypass. Obes Surg. 1997 Dec;7(6):479-84.
Zainabadi K, Courcoulas AP, Awais O, Raftopoulos I Laparoscopic revision of Nissen fundoplication to Roux-en-Y gastric bypass in morbidly obese patients. Surg Endosc. 2008 Dec;22(12):2737-40. doi: 10.1007/s00464-008-9848-5. Epub 2008 Mar 25.
Laparoscopic Revision Roux-en-Y Gastric Bypass Surgery After Previous Anti-rflux Surgery: Intermediate Results
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.